219 related articles for article (PubMed ID: 21428836)
1. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.
Blackstone EA; Fuhr JP
Future Med Chem; 2010 Nov; 2(11):1641-9. PubMed ID: 21428836
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: it's not as simple as cost alone.
Roger SD; Goldsmith D
J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
[TBL] [Abstract][Full Text] [Related]
3. Implementation of the biosimilar pathway: economic and policy issues.
Grabowski H; Long G; Mortimer R
Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
[No Abstract] [Full Text] [Related]
4. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
5. [The industry recommends increased use. Biosimilars are like generics, but still not].
Bergström R; Nyblom K
Lakartidningen; 2010 Oct 20-26; 107(42):2584-5. PubMed ID: 21137555
[No Abstract] [Full Text] [Related]
6. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
7. The generic drug approval process.
Rheinstein PH
Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
[No Abstract] [Full Text] [Related]
8. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
9. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
10. [Biosimilars and medico-economic aspects].
Borget I; Grivel T
Bull Cancer; 2010 May; 97(5):589-95. PubMed ID: 20385522
[TBL] [Abstract][Full Text] [Related]
11. Strategic considerations under the Biologics Price Competition and Innovation Act.
Marquardt JL; Auten SR
Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
[TBL] [Abstract][Full Text] [Related]
12. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
13. Biosimilars: how similar or dissimilar are they?
Roger SD
Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
[TBL] [Abstract][Full Text] [Related]
14. Health economics of market access for biopharmaceuticals and biosimilars.
Simoens S
J Med Econ; 2009 Sep; 12(3):211-8. PubMed ID: 19723019
[TBL] [Abstract][Full Text] [Related]
15. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
Kuhrt K; Chace-Ortiz M
IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
Jelkmann W
Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
[TBL] [Abstract][Full Text] [Related]
18. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
19. Generics, Supergenerics and Patent Strategies--SMi's 13th Annual Meeting.
Edwards C
IDrugs; 2010 Jul; 13(7):433-6. PubMed ID: 20582864
[TBL] [Abstract][Full Text] [Related]
20. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States.
Hennessy S; Leonard CE; Platt R
Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
